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Transancestral GWAS of alcohol dependence 
reveals common genetic underpinnings with 
psychiatric disorders
Liability to alcohol dependence (AD) is heritable, but little is known about its complex polygenic architecture or its genetic 
relationship with other disorders. To discover loci associated with AD and characterize the relationship between AD and other 
psychiatric and behavioral outcomes, we carried out the largest genome-wide association study to date of DSM-IV-diagnosed 
AD. Genome-wide data on 14,904 individuals with AD and 37,944 controls from 28 case–control and family-based studies 
were meta-analyzed, stratified by genetic ancestry (European, n = 46,568; African, n = 6,280). Independent, genome-wide 
significant effects of different ADH1B variants were identified in European (rs1229984; P = 9.8 × 10–13) and African ancestries 
(rs2066702; P = 2.2 × 10–9). Significant genetic correlations were observed with 17 phenotypes, including schizophrenia, 
attention deficit–hyperactivity disorder, depression, and use of cigarettes and cannabis. The genetic underpinnings of AD 
only partially overlap with those for alcohol consumption, underscoring the genetic distinction between pathological and 
nonpathological drinking behaviors.
Excessive alcohol use is a leading contributor to morbidity and mortality. One in 20 deaths worldwide is attributable to alco-hol consumption, as is 5.1% of the global burden of disease1. 
AD, as defined by the Fourth Edition of the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV)2, is a serious psychiatric disorder characterized by toler-
ance, withdrawal, loss of control over drinking, and excessive alco-
hol consumption despite negative health and social consequences. 
Among alcohol drinkers, 12% meet criteria for DSM-IV AD during 
their lifetimes3. In the United States, only 25% of those with AD ever 
receive treatment4.
AD is moderately heritable (49% by a recent meta-analysis)5 and 
numerous genome-wide association studies (GWAS) have aimed to 
identify loci contributing to this genetic variance (see ref. 6 for a 
review). According to one study, common single-nucleotide poly-
morphisms (SNPs) are responsible for as much as 30% of the vari-
ance in AD7, but few have been identified to date. Variants in the 
genes responsible for alcohol metabolism, especially ADH1B and 
ALDH2, have been strongly implicated8–13. The association between 
AD (and related drinking phenotypes) and rs1229984, a missense 
SNP (Arg48His) in ADH1B that affects the conversion of alcohol to 
acetaldehyde, represents one of the largest common-variant effect 
sizes observed in psychiatry, with the His48 allele accelerating etha-
nol metabolism and affording an approximately threefold reduction 
in likelihood of AD across numerous studies8,10. Another functional 
polymorphism, rs671 in ALDH2 (Glu504Lys), strongly affects alco-
hol metabolism by blocking conversion of acetaldehyde to acetate 
and has an even stronger effect on risk for AD, but is rare except in 
some Asian populations8,12,13 ADH1B and ALDH2 polymorphisms, 
however, only explain a small proportion of the heritable variation 
in AD in populations of European or African ancestry.
In this study, the Substance Use Disorders working group of 
the Psychiatric Genomics Consortium (PGC-SUD14) compiled 
the largest numbers of carefully diagnosed alcohol-dependent 
individuals and alcohol-exposed controls to date, from both case–
control and family studies. These included substantial numbers of 
people with European ancestry (EU, n = 46,568, including 38,686 
unrelated individuals) and people with admixed African-American 
ancestry (AA, n = 6,280, including 5,799 unrelated individuals) 
subjects. AD diagnoses were derived from clinician ratings or sem-
istructured interviews following DSM-IV2 criteria. Each study was 
subjected to stringent quality control before conducting GWAS 
within each population of each study, followed by a genome-wide 
meta-analysis. We estimated the SNP-heritability (h2g) of AD 
and examined the extent to which aggregate genetic variation in 
AD is related to traits from 45 other GWAS, including continu-
ous measures of alcohol consumption. We also examined whether 
polygenic risk scores (PRS) derived from these analyses predicted 
alcohol dependence and related measures of problem drinking in 
three independent samples.
Results
GWAS meta-analyses. The transancestral discovery meta-anal-
ysis of GWAS of AD in 28 cohorts (Table 1 and Supplementary 
Table 1) identified a genome-wide significant (GWS; P < 5 × 10–8) 
association in the ADH gene cluster on chromosome 4 (Fig. 1 and 
Table 2). Examining this locus in each population (Fig. 2), rs1229984 
in ADH1B was the strongest associated variant from the analysis 
in EU (z = –7.13, P = 9.8 × 10–13), while rs2066702, also in ADH1B, 
was the most significant variant in AA (z = –5.98, P = 2.2 × 10–9). 
Transancestral modeling reinforced the robust effects of rs1229984 
and other ADH1B SNPs on liability to AD across inverse-variance 
weighted, random effects, and Bayesian models (Supplementary 
Fig. 1 and Supplementary Table 2).
Clumping the ADH locus for linkage disequilibrium (LD; 
r2 < 0.1 within 500 kb) suggested multiple independent signals in 
both populations, with the differing leading alleles reflecting dif-
ferent LD structures and allele frequencies in each population 
(Table 2 and Supplementary Fig. 2). Conditional analyses control-
ling for rs1229984 and rs2066702 had limited power, but results 
showed limited attenuation of effect sizes between marginal and 
conditional analyses, consistent with the existence of additional 
independent effects in the region (Supplementary Table 3 and 
Supplementary Fig. 3). Suggestive independent signals in the 
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genotyped cohorts included trialleleic variant rs894368 (marginal 
z = –4.57, P = 4.9 × 10–6; conditional z = 4.53, P = 5.8 × 10–6) and 
insertion rs112346244 (marginal odds ratio = 0.912, s.e. = 0.024, 
z = –3.81, P = 1.4 × 10–4; conditional odds ratio = 0.883, s.e. = 0.025, 
z = –5.05, P = 4.5 × 10–7; Supplementary Table 3). Several additional 
variants that were prioritized in the conditional analysis, while not 
significant, were in moderate to strong LD with rs698 (marginal 
odds ratio = 1.115, s.e. = 0.021, z = 5.19, P = 2.1 × 10–7; conditional 
odds ratio = 1.084, s.e. = 0.021, z = 3.78, P = 1.6 × 10–4), a functional 
ADH1C variant with a role in AD8,11.
A single novel SNP on chromosome 3, rs7644567, also reached 
GWS in the meta-analysis (z = 5.68, P = 1.36 × 10–8; Supplementary 
Fig. 4). Potential biological associations with rs7644567, including 
chromatin contacts (Supplementary Fig. 5) and cerebellar expression 
of RBMS3, are summarized in Supplementary Methods. However, 
rs7644567 did not replicate in two independent AA samples (Yale–
Penn 2 and Collaborative Study on the Genetics of Alcoholism 
(COGA) African-American Family GWAS (AAfGWAS)) or the 
independent FINRISK cohort; all three replication cohorts esti-
mated effects of the minor allele in the opposite direction of the dis-
covery meta-analysis (Supplementary Table 4; see Supplementary 
Information). The SNP is also rare in most EU samples (minor allele 
frequency (MAF) < 0.01), with the current GWAS results primar-
ily attributable to AA cohorts, along with the Finnish Twin cohort 
(FinnTwin) and the Finnish Nicotine Addiction Genetics Project 
(NAG-Fin). The EU cohorts in the discovery meta-analysis show no 
evidence of association of AD with the SNPs in strongest LD with 
rs7644567 in African (rs13098461; z = 0.27, P = 0.79) or Finnish 
(rs9854300; z = 0.10, P = 0.92) reference samples (Supplementary 
Methods). Based on the clear lack of replication, there is insufficient 
evidence to conclude that rs7644567 is associated with AD based on 
the current results.
There was limited genome-wide evidence for heterogeneity 
across all cohorts, within ancestry, between ancestries, or between 
study designs within ancestry (Supplementary Methods and 
Supplementary Figs. 6–8). Evidence for inflation from population 
stratification or other confounding was also limited in the discov-
ery meta-analysis (λ = 0.962; Supplementary Fig. 9) and within EU 
(λ = 1.053, LD score regression (LDSR) intercept = 1.018) and AA 
(λ = 1.007, LDSR intercept = 0.991–0.997; Supplementary Methods). 
Gene-level association testing with MAGMA15 did not identify any 
additional significant genes in EU or AA (Supplementary Table 5 
and Supplementary Methods), likely due to lack of power.
Heritability and genetic correlations. Liability-scale SNP-
heritability of AD was estimated at h2g = 0.090 (s.e. = 0.019, z = 4.80, 
P = 8.02 × 10–7) in the meta-analysis of unrelated EU samples. 
Exclusion of the ADH1B locus did not substantially modify this 
estimate (h2g = 0.089, s.e. = 0.0185). Nominally significant poly-
genic signal for the meta-analysis of unrelated AA individuals 
was observed based on LDSR with scores computed from 1000 
Genomes Project African populations (z = 2.12, P = 0.017), but 
the quantitative estimate of h2g was unstable depending on the 
choice of reference panel, reflecting the challenge of correctly 
specifying LDSR and robustly modeling LD for the AA population 
(Supplementary Methods).
Significant genetic correlation with AD in EU was observed for 
17 traits after correction for multiple testing (P < 1.11 × 10–3 for 45 
tested traits; Fig. 3 and Supplementary Table 6). The largest positive 
correlations were with smoking initiation (rg = 0.708, s.e. = 0.134, 
P = 1.3 × 10–7) and lifetime cannabis initiation (rg = 0.793, s.e. = 0.217, 
P = 2.5 × 10–4), as well as with other psychiatric disorders, especially 
schizophrenia (rg = 0.357, s.e. = 0.054, P = 3.2 × 10–11), attention def-
icit–hyperactivity disorder (rg = 0.444, s.e. = 0.097, P = 4.2 × 10–6), 
and depression (rg = 0.561, s.e. = 0.085, P = 3.5 × 10–11). Educational 
attainment (rg = –0.468, s.e. = 0.066, P = 9.7 × 10–13) and age at first 
birth (higher values indicate that participants were older when they 
had their first child; rg = –0.626, s.e. = 0.104, P = 2.0 × 10–9) showed 
significant inverse genetic correlation with AD, suggesting that 
liability to AD risk was genetically related to lower educational 
attainment and lower age at which the participant had his or her 
first child.
Unexpected patterns of genetic correlation were observed when 
comparisons were made to other alcohol-related measures, indi-
cating that those measures reflect aspects of alcohol use that are 
genetically distinguishable. AD was genetically correlated with 
alcohol consumption in a meta-analysis of the Alcohol Genome-
wide Association (AlcGen) and Cohorts for Aging and Research in 
Genomic Epidemiology Plus (CHARGE+ ) consortia16 (rg = 0.695, 
s.e. = 0.155, P = 6.9 × 10–6), but only modestly with alcohol cons-
umption from the recent large UK Biobank analysis17 (rg = 0.371, 
s.e. = 0.092, P = 5.2 × 10–5). No significant genetic correlation was 
observed between AD and a recent GWAS of the alcohol use disor-
ders identification test (AUDIT) in a 23andMe cohort18 (rg = 0.076, 
s.e. = 0.171, P = 0.656), perhaps due to the low levels of drinking 
and drinking-related problems in that population18. AD is, however, 
nominally genetically correlated with GWAS of delay discounting in 
the 23andMe sample19 (rg = 0.487, s.e. = 0.178, P = 6.0 × 10–3).
Association with ADH1B expression. Based on the strong observed 
association with rs1229984 and rs2066702, we examined whether 
other variants affecting ADH1B expression (expression quantita-
tive trait loci) were also associated with AD using GTEx v7 results 
(https://www.gtexportal.org/)20. Three variants, rs11939328 (EU, 
P = 0.78; AA P = 0.98; transancestral (trans), P = 0.78), rs10516440 
(EU, P = 3.97 × 10–6; AA, P = 1.97 × 10–3; trans, P = 4.72 × 10–8), and 
rs7664780 (EU, P = 0.87; AA, P = 0.083; trans, P = 0.405), were 
selected after LD-informed clumping and the exclusion of vari-
ants in LD (r2 > 0.1) with the GWS coding alleles rs1229984 and 
rs2066702. Of these, only rs10516440 (AD conditional analyses: 
EU, P = 1.34 × 10–3; AA, P = 0.013; trans, P = 7.44 × 10–5) was a sig-
nificant multitissue expression quantitative trait locus in random 
effects analysis for ADH1B (fixed effects test statistic SFE = 319.4, 
heterogeneity test statistic SHet = 27.6, combined P = 1.4 × 10–76), 
ADH1A (SFE = 139.4, SHet = 6.6, combined P = 6.72 × 10–33), 
and ADH1C (SFE = 167.3, SHet = 8.9, combined P = 1.9 × 10–39). 
Rs10516440 is an LD proxy (r2 > 0.9) of rs6827898 (Table 2) in pop-
ulations of European and African descent. These variants are both 
located in an intergenic region in the ADH gene cluster between 
ADH1C and ADH7. In line with the fact that the protective coding 
alleles are associated with increased activity of the enzyme encoded 
by ADH1B, the major allele rs10516440*A was associated with 
increased ADH1B expression and reduced AD risk.
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Fig. 1 | Manhattan plot of discovery transancestral meta-analysis showing 
strong evidence for rs1229984 in ADH1B. Results from the discovery meta-
analysis of all cohorts (ncase =  14,904; ncontrol =  37,944) for association of 
genome-wide SNPs with AD under a fixed effects meta-analysis weighted 
by effective sample size. Dashed red reference line indicates GWS after 
correction for multiple testing (P <  5 ×  10–8).
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Table 1 | Descriptive statistics for cohorts in the meta-analysis of AD
Dataset PMiD Male 
(%)
Ages 
(years)
eu AA
n total n unrelated n total n unrelated
case control case control case control case control
case–control: logistic regression
Comorbidity and Trauma 
Study
23303482 56% 18–67 572 817 572 817 – – – –
Christchurch Health and 
Development Study
23255320 48% 16–30 112 500 112 500 – – – –
COGA case–control cohort 
(COGA-cc)
20201924 54% 18–79 583 363 583 363 – – – –
Family Study of Cocaine 
Dependence
18243582 51% 18–60 266 174 266 174 255 241 255 241
German Study of the 
Genetics of Alcoholism 
(GESGA)
19581569 65% 18–84 1,314 2,142 1,314 2,142 – – – –
Gene–Environment 
Development Initiative 
(GEDI): Great Smoky 
Mountains Study (GSMS)
8956679 57% 9–26 42 565 42 565 – – – –
Center on Antisocial Drug 
Dependence
25637581 70% 13–20 400 577 400 577 51 51 51 51
Phenomics and Genomics 
Sample
28371232 57% 18–74 37 523 37 523 – – – –
Collaborative Study on 
the Genetics of Nicotine 
Dependence (COGEND 
Nico)
17158188 34% 25–82 135 272 135 272 46 232 46 232
COGEND Study of 
Addiction: Genetics and 
Environment (COGEND 
SAGE)
20202923 37% 18–77 311 225 311 225 104 103 104 103
Spit For Science 24639683 36% > 18 252 1,863 252 1,863 74 841 74 841
NIAAA n/a 67% > 18 442 206 442 206 404 110 404 110
Mayo Clinic Center for the 
Individual Treatment of 
Alcohol Dependence
25290263 55% ≥ 18 378 646 378 646 – – – –
Alcohol Dependence in 
African Americans
n/a 57% 18–69 – – – – 794 297 794 297
Family-based, twins, and siblings: generalized estimating equations
Brisbane Longitudinal Twin 
Study
23187020 43% 18–30 60 938 51 546 – – – –
GEDI Virginia Twin Study 
on Adolescent Behavioral 
Development (VTSABD)
9294370 38% 8–32 209 503 188 318 – – – –
Minnesota Center for Twin 
and Family Research
23942779 41% 16–21 609 2,100 553 1,274 – – – –
Center for Education and 
Drug Abuse Research
21514569 63% 16–34 59 200 54 152 – – – –
Swedish Twin Registry 23137839 47% 40–83 76 8,311 76 6,112 – – – –
Yale–Penn 24166409 58% 16–79 1,094 301 1,004 252 – – – –
Family-based, large, or complex pedigrees: logistic mixed model
COGA family cohort 
(COGA-fam)
23089632 45% 12–88 605 682 168 138 – – – –
Australian Alcohol and 
Nicotine Studies
21529783 45% 18–82 1,571 3,069 1,111 805 – – – –
Continued
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Associations with other GWS loci. We examined results for the 
eight independent variants associated at GWS levels with alco-
hol consumption in the UK Biobank17 (Supplementary Table 7). 
Among the UK Biobank findings, three of the four reported vari-
ants in the ADH region of chromosome 4 (rs145452708, a proxy for 
rs1229984 with D' = 1, rs29001570 and rs35081954) were associated 
in the present study with AD (P values ranging from 3.5 × 10–5 to 
2.3 × 10–10) with sign-concordant effects; the remaining variant was 
excluded from our analysis due to MAF < 0.01. The UK Biobank 
lead variant in KLB, rs11940694, was nominally associated with AD 
(P = 0.0097), though this did not surpass multiple-testing correction 
for the eight GWS alcohol consumption loci. We saw little evidence 
(P > 0.2) for association of AD with the reported loci at GCKR and 
CADM2, which may be due to differences in power for the given 
effect size or because these genes exert an influence on liability to 
consume alcohol but not later problems. The locus on chromosome 
18 showed limited regional association with AD, but the index vari-
ant was not present in our analysis because it no longer appears in 
the 1000 Genomes Project Phase 3 reference panel21.
Polygenic risk score analyses. PRS based on our meta-analysis of 
AD were significantly predictive of AD outcomes in all three tested 
external cohorts. PRS derived from the unrelated EU GWAS pre-
dicted up to 0.51% of the variance in past month alcohol use disorder 
in the Avon Longitudinal Study of Parents and Children (ALSPAC; 
P = 0.0195; Supplementary Fig. 10a) and up to 0.3% of problem 
drinking in Generation Scotland (P = 7.9 × 10–6; Supplementary 
Fig. 10b) as indexed by the CAGE (Cutting down, Annoyance by 
criticism, Guilty feelings, and Eye-openers) questionnaire. PRS 
derived from the unrelated AA GWAS predicted up to 1.7% of the 
variance in alcohol dependence in the COGA AAfGWAS cohort 
(P = 1.92 × 10–7; Supplementary Fig. 10c).
Notably, PRS derived from the unrelated EU GWAS showed 
much weaker prediction (maximum r2 = 0.37%, P = 0.01; 
Supplementary Fig. 10d) in the COGA AAfGWAS than the ances-
trally matched AA GWAS-based PRS despite the much smaller dis-
covery sample for AA. In addition, the AA GWAS-based AD PRS 
also still yielded significant variance explained after controlling 
for other genetic factors (r2 = 1.16%, P = 2.5 × 10–7). Prediction 
of CAGE scores in Generation Scotland remained significant 
and showed minimal attenuation (r2 = 0.29%, P = 1.0 × 10–5) after 
conditioning on PRS for alcohol consumption derived from UK 
Biobank results17. In COGA AAfGWAS, the AA PRS derived from 
our study continued to predict 1.6% of the variance in alcohol 
dependence after inclusion of rs2066702 genotype as a covariate, 
indicating independent polygenic effects beyond the lead ADH1B 
variant (Supplementary Methods).
Power analysis. Power analyses indicated that the current meta-
analysis is expected to have at least 41% power to detect very com-
mon variants (MAF ≥ 0.25) with odds ratios ≥ 1.10 at P < 5 × 10–8 
and 63% power for P < 1 × 10–6 (Supplementary Fig. 11). Power at 
P < 1 × 10–6 is relevant because only five loci reach that threshold 
in the current meta-analysis. Power is lower for less-common vari-
ants (MAF ≤ 0.05) even with odds ratios ≥ 1.20 at P < 1 × 10–6 (60% 
power) and P < 5 × 10–8 (38% power).
For perspective, power computations using the observed dis-
tribution of top effects for other large GWAS of polygenic traits 
suggest that we observed significantly fewer GWS loci for AD 
than would be expected if the loci had true effect sizes and allele 
frequencies similar to schizophrenia (expected: 25.4 loci, 95% 
confidence interval: 21–30) or obesity (expected: 8.9 loci, 95% con-
fidence interval: 6–12), but not fewer than would be expected for 
effect sizes similar to major depression (Supplementary Methods 
and Supplementary Table 8).
Discussion
To our knowledge, this is the largest GWAS of rigorously defined 
AD to date, comprising 14,904 AD individuals and 37,944 
controls. We identified known loci in ADH1B that differed between 
EU and AA, as well as previously uncharacterized genetic correla-
tions between AD and psychiatric disorders (for example, schizo-
phrenia), tobacco and cannabis use, and social (for example, 
socioeconomic deprivation) and behavioral (for example, educa-
tional attainment) outcomes. Analyses also revealed a genetic dis-
tinction between GWAS results for alcohol consumption and AD. 
Dataset PMiD Male 
(%)
Ages 
(years)
eu AA
n total n unrelated n total n unrelated
case control case control case control case control
Irish Affected Sib Pair Study 
of Alcohol Dependence
15770118 50% 17–84 721 1,814 436 1,802 – – – –
Yale–Penn 24166409 51% 16–79 – – – – 1,607 1,070 1,263 933
Summary statistics
Netherlands Study of 
Depression and Anxiety & 
Netherlands Twin Registry
18197199 31% > 18 390 1,633 390 1,633 – – – –
Finnish Nicotine Addiction 
Genetics Project (NAG-Fin)
17436240 52% 30–92 439 1,137 439 1,137 – – – –
FinnTwin12 17254406 47% 20–27 88 874 88 874 – – – –
National Longitudinal Study 
of Adolescent to Adult 
Health (Add Health)
25378290 47% 24–34 768 2,981 768 2,981 – – – –
Helsinki Birth Cohort Study 16251536 43% 56–70 36 1,583 36 1,583 – – – –
Total 11,569 34,999 10,206 28,480 3,335 2,945 2,991 2,808
Overview of numbers of individuals with AD (cases) and controls from each cohort in the current analysis, including the number of genetically unrelated individuals. Cohorts are listed by study design and 
analysis method. Sample sizes are listed after quality control exclusions and stratified by ancestry group. PubMed identifiers (PMID) are listed for previous publications describing each cohort, along with 
the percentage of male samples and the age range in the cohort.
Table 1 | Descriptive statistics for cohorts in the meta-analysis of AD (continued).
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Although larger sample sizes can be amassed by focusing on quan-
titative measures of consumption, only the upper tail is relevant to 
AD (as a medical diagnosis), and even that does not capture other 
aspects of disordered drinking (for example, loss of control, with-
drawal) directly. Conversely, cases derived from electronic medical 
records (for example, International Classification of Diseases (ICD) 
codes) result in a high rate of false negatives, while self-screening 
instruments (for example, AUDIT scores) are best suited to analyses 
of disordered drinking when a sufficiently high threshold or score 
cutoff is applied to focus on severity. Our study has the advantage 
of greater diagnostic precision via use of semistructured interviews 
to diagnose AD systematically in a majority of the constituent stud-
ies and therefore greater interpretability in the context of clinically 
important AD.
The GWS SNPs reaffirm the importance of functional variants 
affecting alcohol metabolism to the risk of AD. The top associa-
tion in ADH1B, rs1229984, is a missense variant that is amongst 
the most widely studied in relation to alcohol use, misuse, and 
Table 2 | Top ten loci from the meta-analyses of AD by ancestry
SNP chr BP A1 A2 Gene A1 allele 
frequency
iNFo  
score
effect size  
(oR)
Discovery meta-analysis  
P value
eu AA eu AA eu AA eu AA Trans
Top clumped variants in transancestral meta-analysis (14,904 cases; 37,944 controls)
 rs7644567* 3 29201672 A G RBMS3 0.964 0.705 0.96 1.00 – 1.229 3.94 ×  10–4 6.64 ×  10–6 1.36 ×  10–8
 rs2066702 4 100229017 A G ADH1B – 0.215 – 0.99 – 0.731 – 2.21 ×  10–9 2.21 ×  10–9
 rs1229984 4 100239319 T C ADH1B 0.040 0.014 0.90 0.91 0.486 0.912 9.79 ×  10–13 3.48 ×  10–1 2.18 ×  10–11
 rs1789912 4 100263942 T C ADH1C 0.418 0.132 1.00 1.02 1.106 1.211 1.98 ×  10–7 1.32 ×  10–3 1.47 ×  10–9
 rs6827898 4 100295863 A G (ADH region) 0.123 0.112 0.96 0.94 1.145 1.270 5.21 ×  10–7 9.31 ×  10–4 2.97 ×  10–9
rs894368 4 100309313 A C (ADH region) 0.309 0.386 0.99 0.96 0.887 0.981 1.93 ×  10–8 9.73 ×  10–1 3.30 ×  10–7
rs2461618 7 68667233 A G – – 0.088 – 0.98 – 0.669 – 6.30 ×  10–7 6.30 ×  10–7
rs116338421 8 145761256 C G ARHGAP39 – 0.172 – 0.97 – 0.755 – 4.86 ×  10–7 4.86 ×  10–7
rs79171978 12 17798824 C G – 0.099 0.027 0.99 0.99 1.201 1.016 5.47 ×  10–8 8.18 ×  10–1 5.98 ×  10–7
rs8017647 14 32456358 T C – 0.792 0.565 1.00 0.99 0.901 0.923 8.05 ×  10–6 4.71 ×  10–2 1.03 ×  10–6
Top clumped variants in African ancestry meta-analysis (3,335 cases; 2,945 controls)
rs5781337 1 223883425 CA C – 0.263 0.212 0.98 0.93 1.007 0.664 8.85 ×  10–1 1.62 ×  10–7 6.59 ×  10–2
rs143258048 3 75982870 A AC ROBO2 – 0.028 – 0.88 – 0.490 – 1.86 ×  10–6 –
rs3857224 4 100129685 T C ADH6 0.315 0.585 0.99 1.00 0.970 0.814 2.40 ×  10–1 5.86 ×  10–7 2.36 ×  10–3
 rs2066702 4 100229017 A G ADH1B – 0.215 – 0.99 – 0.731 – 2.21 ×  10–9 2.21 ×  10–9
rs2461618 7 68667233 A G – – 0.088 – 0.98 – 0.669 – 6.30 ×  10–7 6.30 ×  10–7
rs116338421 8 145761256 C G ARHGAP39 – 0.172 – 0.97 – 0.755 – 4.86 ×  10–7 4.86 ×  10–7
rs79016499 11 93010988 T C – – 0.066 – 0.93 – 1.729 – 1.36 ×  10–6 –
rs10784244 12 62035165 G A – 0.153 0.484 1.00 1.00 1.041 1.226 6.26 ×  10–2 1.04 ×  10–6 2.49 ×  10–4
rs17199739 16 25444288 G A – 0.176 0.096 0.99 0.96 0.994 0.693 4.25 ×  10–1 1.11 ×  10–6 8.66 ×  10–3
rs740793 17 3846353 G A ATP2A3 0.453 0.350 0.97 0.97 0.996 1.370 4.66 ×  10–1 1.48 ×  10–6 3.44 ×  10–1
Top clumped variants in european ancestry meta-analysis (11,569 cases; 34,999 controls)
 rs1229984 4 100239319 T C ADH1B 0.040 0.014 0.90 0.91 0.486 0.912 9.79 ×  10–13 3.48 ×  10–1 2.18 ×  10–11
rs3811802 4 100244221 G A ADH1B 0.454 0.529 0.96 0.96 1.162 0.914 2.40 ×  10–8 2.19 ×  10–2 1.22 ×  10–4
rs113659074 4 100252308 T G ADH1B 0.068 0.093 0.98 0.95 0.800 1.166 1.54 ×  10–6 6.63 ×  10–2 2.99 ×  10–4
rs1229863 4 100252386 A T ADH1B 0.174 0.038 0.99 0.99 1.145 1.254 7.80 ×  10–7 4.26 ×  10–2 9.28 ×  10–8
 rs1154445 4 100288521 G T (ADH region) 0.425 0.134 0.97 0.99 1.137 1.211 1.80 ×  10–7 2.63 ×  10–2 1.48 ×  10–8
 rs6827898 4 100295863 A G (ADH region) 0.123 0.112 0.96 0.94 1.145 1.270 5.21 ×  10–7 9.31 ×  10–4 2.97 ×  10–9
rs894368 4 100309313 A C (ADH region) 0.309 0.386 0.99 0.96 0.887 0.981 1.93 ×  10–8 9.73 ×  10–1 3.30 ×  10–7
rs79171978 12 17798824 C G – 0.099 0.027 0.99 0.99 1.201 1.016 5.47 ×  10–8 8.18 ×  10–1 5.98 ×  10–7
rs4388946 12 17935154 C A – 0.240 0.297 0.99 0.98 1.137 0.950 7.14 ×  10–7 1.87 ×  10–1 7.05 ×  10–5
rs34929220 15 69769635 T C DRAIC 0.690 0.937 0.90 0.94 0.893 1.028 1.02 ×  10–6 8.38 ×  10–1 7.38 ×  10–6
Top ten nominally independent variants from the discovery transancestral (trans.; ncase =  14,904; ncontrol =  37,944) meta-analysis and the discovery meta-analyses in AA (ncase =  3,335; ncontrol =  2,945) and 
EU (ncase =  11,569; ncontrol =  34,999) ancestry cohorts, respectively. Independent variants are identified based on clumping for LD (pairwise r2 <  0.1) in 1000 Genomes Project Phase 3 data21. EU results are 
clumped using European ancestry reference samples, AA results are clumped using African ancestry reference samples from the American Southwest, and transancestral results are clumped using merged 
European and African ancestry reference samples. P values and allele frequencies are reported from two-tailed tests of association with AD in fixed-effects meta-analyses weighted by effective sample 
size. Bold P values indicate GWS after correction for multiple testing within the analysis (P <  5 ×  10–8). Odds ratios (OR) and INFO scores are reported from the meta-analyses of the subset of unrelated 
individuals within each ancestry. Variants are sorted by chromosome (Chr) and base pair (BP) position for genome build hg19, with genes annotated by Ensembl VEP49. Allele frequency and OR are given 
with respect to allele 1 (A1). SNPs included in the transancestral meta-analysis were not conditioned on being analyzed in both the EU and AA analyses. For instance, a SNP of strong effect in one group 
may not be sufficiently common or well-imputed for analysis in the other ancestral group (for example, rs2066702 is not found in non-African populations but is among the top ten in the transancestral 
analysis due to strong effects in the AA group). For rs7644567 (denoted with *), the SNP did not pass quality control in a sufficient number of cohorts to meet the minimum sample-size requirement for 
inclusion in the EU-only analyses—it is only represented among EU cohorts by summary statistics from two Finnish cohorts—but allele frequency, INFO score, and meta-analyzed P values from the Finnish 
summary statistics are reported since they contribute to the transancestral meta-analysis.
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dependence8–10. The resulting amino acid substitution (Arg48His) 
increases the rate at which alcohol dehydrogenase 1B oxidizes 
ethanol to acetaldehyde8. Studies on Asian populations in which 
the derived allele is common demonstrated strong protection 
against the development of AD8,9,13. In EU and AA, the protective 
allele is present at much lower frequencies (EU, MAF = 0–4%; AA, 
MAF < 1%); nevertheless, recent large-scale studies have shown an 
association between this locus and alcohol consumption and prob-
lems at GWS levels in EU with similar effect size8–10. The lead vari-
ant in AA cohorts, rs2066702 (Arg370Cys), is another functional 
missense variant in ADH1B, and it also encodes an enzyme with an 
increased rate of ethanol oxidation8. The allele encoding Cys370 is 
common in AA, but rare in other populations8. Our results clearly 
show that these two different functional SNPs in ADH1B both affect 
risk for alcoholism, with their relative importance dependent upon 
allele frequency in the population studied. There is a suggestion of 
additional independent effects in the chromosome 4 region, but 
larger studies will be needed to evaluate this.
The only other locus to reach significance was rs7644567 on 
chromosome 3, primarily driven by AA cohorts. The locus failed 
to replicate in two small, independent AA samples, and in the only 
European cohort with even a modest allele frequency (FINRISK), 
the effect was in the opposite direction. There have also been dis-
cussions about whether the standard GWAS significance threshold 
should be applied to the more genetically diverse African-ancestry 
cohorts22,23 and about the possibility of confounding from nonlin-
ear relationships between phenotypes and ancestry-informative 
markers like rs7644567 in admixed samples24, all of which increase 
our skepticism regarding this finding. There is, therefore, insuf-
ficient evidence at this time to conclude that rs7644567 is associ-
ated with alcohol dependence. Analyses of much larger samples of 
African ancestry will be needed to resolve this.
Despite limited SNP-level findings, there is significant evi-
dence for polygenic effects of common variants in both EU and 
AA cohorts. The estimated h2g = 0.09 for AD in EU is only mod-
estly lower than those recently reported for alcohol consumption 
(h2g = 0.13)17 and AUDIT scores (h2g = 0.12)18, and it is comparable to 
estimates derived for cigarettes-per-day25. Our h2g estimate is lower 
than that of a prior report7, likely reflecting a combination of differ-
ences in estimation method (genomic relatedness matrix restricted 
maximum likelihood (GREML) versus LDSR) and greater heteroge-
neity in ascertainment strategy across samples in the current study 
(see refs 26–28). The latter is especially relevant in comparing h2g from 
that prior single cohort to our meta-analysis, which included 
cohorts with a wide range of ages at ascertainment, cultural envi-
ronments, and ascertainment strategies, including enrichment for 
other substance use disorders. Similarly to other psychiatric disor-
ders (for example, schizophrenia), a much larger sample size will 
potentially aid in overcoming across-sample heterogeneity and will 
capture a greater proportion of genetic variance.
Comparing our GWAS to recent GWAS of alcohol consumption 
measures suggests that the liability underlying normative patterns of 
alcohol intake and AD are only partially overlapping. Genome-wide 
genetic correlations were significantly < 1 with log-scaled alcohol 
consumption by participants in AlcGen and CHARGE+ Consortia 
cohorts16 (rg = 0.695, s.e. = 0.15, one-tailed P = 0.024 for rg < 1) and 
in the UK Biobank17 (rg = 0.371, s.e. = 0.092, one-tailed P = 3.2 × 10–12 
for rg < 1). We also observed only partial replication of the eight loci 
significantly associated with consumption in the UK Biobank, with 
strongest results from SNPs in the ADH region, including a proxy 
for rs1229984. In addition, there was no significant correlation 
with GWAS of log-scaled AUDIT scores in 23andMe participants18 
(rg = 0.076, s.e. = 0.171, two-tailed P = 0.656). Subsequent analyses 
suggest these estimates are sensitive to sample characteristics, with 
somewhat higher genetic correlations reported in analysis of alco-
hol consumption in the full UK Biobank29 (rg = 0.75) and of AUDIT 
in combined data from 23andMe participants and UK Biobank30 
(rg = 0.39). Notably, initial UK Biobank data includes a subset of par-
ticipants recruited for a study of smoking and lung function in the 
Discovery meta-analysis (14,094 cases; 37,944 controls)
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Fig. 2 | Regional plots for the ADH1B locus (rs1229984) in the transancestral 
discovery, AA, and eu meta-analyses. a–c, Results of fixed effects meta-
analysis with effective sample-size weights for the ADH1B locus in (a) 
all cohorts (ncase =  14,904; ncontrol =  37,944); (b) AA cohorts (ncase =  3,335; 
ncontrol =  2,945); and (c) EU cohorts (ncase =  11,569; ncontrol =  34,999). Red 
reference line indicates the GWS threshold after correction for multiple 
testing within each analysis (P <  5 ×  10–8). Within ancestry, colored points 
reflect the degree of LD (pairwise r2) to the index variant (purple diamond) 
in 1000 Genomes Project reference data21 for individuals of (b) African or (c) 
European ancestry, respectively. LD structures in the two ancestries differ, 
so for the transancestral sample (a), LD is not given, indicted by gray points. 
Two-tailed tests used for all analyses. Chr4, chromosome 4.
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first analysis17, which may have resulted in collider bias31 and con-
tributed to the initial lower genetic correlation.
One key factor in interpreting the differences between these traits 
and AD is that the distribution of consumption levels and AUDIT 
scores can be highly skewed in population samples, with most indi-
viduals at the low (nonpathological) end of the spectrum. This effect 
may be especially pronounced among the older, healthy volunteers 
of the UK Biobank cohort32 and in the 23andMe cohort, which is 
more educated and has higher socioeconomic status than the gen-
eral US population18. We hypothesize that the variants that affect 
consumption at lower levels may differ substantively from those that 
affect very high levels of consumption in alcohol dependent indi-
viduals, who are also characterized by loss of control over intake33. 
This appears to be the case in studies that used specific cut-offs to 
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Fig. 3 | Genetic correlations between 45 traits and alcohol dependence in europeans. Genetic correlation results from LDSR with the meta-analysis of AD 
in unrelated EU individuals (ncase =  10,206; ncontrol =  28,480). After Bonferroni correction, significant correlations were observed with 17 traits and disorders 
(P <  1.1 ×  10–3; bold), with nominally significant results for eight additional traits and disorders (P <  0.05; italics) based on two-tailed tests of the estimated 
genetic correlation with block jackknife standard errors. Error bars indicate 95% confidence intervals; arrows indicate intervals extending above 1 or 
below –1. Vertical gray reference line corresponds to the null hypothesis of no genetic correlation with AD. Phenotypes are organized by research domain. 
ADHD, attention deficit–hyperactivity disorder; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; GGT, gamma-glutamyl transferase; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.
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harmonize AUDIT scores with AD data30,34. The larger of these stud-
ies30 reports that the genetic correlation between AD and AUDIT 
scores is maximized at an AUDIT cutoff ≥ 20 (with controls defined 
as those scoring ≤ 4; rg = 0.90). Notably, that study also found that 
a score reflecting items related to problem drinking (AUDIT-P) 
resulted in a stronger genetic correlation (rg = 0.64) than a score 
related to alcohol consumption alone (rg = 0.33). The strong genetic 
correlation of AD with lower educational attainment and lower 
socioeconomic status (i.e., higher Townsend deprivation), in contrast 
to positive genetic correlations of education with consumption17 and 
AUDIT scores related to consumption30, further underscore this dis-
tinction between normative or habitual levels of alcohol intake and 
diagnosed AD, at least in the respective populations studied.
The current analysis identified robust genetic correlation of AD 
with a broad variety of psychiatric outcomes. This correlation was 
strongest for aspects of negative mood, including neuroticism and 
major depression, as also seen in twin studies35,36 and through recent 
specific molecular evidence for pleiotropy37,38. Taken together with 
evidence from other recent genomic studies37, and with null correla-
tions for other GWAS of alcohol consumption but not for measures 
of problem drinking (for example, AUDIT-P), these findings sug-
gest that major depression may primarily share genetic liability with 
alcohol use at pathological levels.
AD was also strongly genetically correlated with poor educa-
tional and socioeconomic outcomes and marginally correlated with 
measures of risk-taking. Nominally significant genetic correlations 
with delay discounting (i.e., favoring immediate rewards) and risk-
taking, and the strong genetic correlation of AD with attention defi-
cit–hyperactivity disorder, cigarette smoking, and cannabis use, may 
similarly reflect a shared genetic factor for risk-taking and reduced 
impulse control. Common genetic liability to early, risky behaviors 
is characteristic of both AD39 and age of first birth40. The observed 
negative genetic correlation with age of first birth is consistent both 
with risk-taking and with the significant genetic correlations of AD 
with lower socioeconomic status, as indexed by higher neighbor-
hood Townsend deprivation score and lower educational attainment. 
Lower socioeconomic status is correlated with both AD41 and age of 
first birth42, and the current study suggests that shared genetic liabili-
ties may be one potential mechanism for their observed relationship. 
However, the question of whether these genetic correlations repre-
sent causal processes, horizontal pleiotropy, or the impact of unmea-
sured confounders should be explored in the future43.
Lower genetic correlations were observed for most biomedi-
cal and anthropometric outcomes. Liver enzymes GGT and ALT, 
once proposed as possible biomarkers for alcohol abuse44, showed 
only nominal evidence for genetic correlation with AD, and neither 
survived multiple-testing correction. Notably, we did not find any 
association between AD and body-mass index (BMI). Negative 
genetic correlations with BMI were previously reported for both 
alcohol consumption17 and AUDIT scores18, but there is prior evi-
dence that BMI has differing underlying genetic architectures in the 
context of AD and outside of that context45. The negative genetic 
correlations observed in those studies are consistent with studies of 
light to moderate drinking, which is also associated with healthier 
lifestyle behaviors, while heavy and problematic drinking is typi-
cally associated with weight gain46.
This study benefited from precision in diagnostic assessment 
of AD, known alcohol exposure in a majority of the controls, and 
careful quality control that excluded overlap of individuals between 
studies. Despite these strengths, our sample size was insufficient to 
identify additional GWS loci robustly. Power analyses indicate that 
additional SNPs associated with AD are likely to have small effect 
sizes, smaller than schizophrenia47 and more consistent with more 
common psychiatric disorders (for example, major depression48). 
This supports the pressing need for collection of large numbers 
of well-characterized cases and controls. The differences between 
our results and the study of AUDIT scores18 highlight that ascer-
tainment and trait definition are critically important and must be 
taken into account. Careful study of how screening tools, such as 
the AUDIT, correlate with genetic liability to AD (as defined by 
DSM-IV or similar) could substantially boost sample sizes for 
future AD GWAS. There is also a continued need to characterize 
the genetic architecture of AD in non-EU populations.
We show a previously unreported genetic distinction between 
drinking in the pathological range (AD) and habitual drinking that 
does not cross the threshold into pathology or dependence and does 
not capture behavioral aspects of disordered drinking. Larger future 
samples will allow us to uncover additional pleiotropy between 
pathological and nonpathological alcohol use, as well as between 
AD and other neuropsychiatric disorders.
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Methods
Samples. The Substance Use Disorders working group of the Psychiatric 
Genomics Consortium (PGC-SUD14) collected individual genotypic data from 
14 case–control studies and nine family-based studies and summary statistics 
from GWAS of AD from five additional cohorts (Table 1). AD was defined as 
meeting criteria for a DSM-IV2 (or, for one cohort, DSM-IIIR50; a very similar 
construct; see Supplementary Note) diagnosis of AD. Diagnoses were derived 
either from clinician ratings or semistructured interviews. Excepting three cohorts 
with population-based controls (n = 7,015), all controls were screened for AD. 
Individuals with no history of drinking alcohol and those meeting criteria for 
DSM-IV alcohol abuse were excluded as controls where possible (Supplementary 
Information and see Nature Research Reporting Summary). This study was 
approved by the institutional review board (IRB) of Washington University in 
St. Louis and was conducted in accordance with all relevant ethical regulations. 
Each contributing cohort obtained informed consent from their participants and 
received ethics approvals for their study protocols from their respective review 
boards in accordance with applicable regulations.
Quality control and imputation. Data for the cohorts that shared raw genotypes 
were deposited to a secure server for uniform quality control (QC). QC and 
imputation of the 14 case–control studies was performed using the Ricopili 
pipeline (https://github.com/Nealelab/ricopili). For the nine family-based 
cohorts, an equivalent pipeline, Picopili (https://github.com/Nealelab/picopili), 
was developed for QC, imputation, and analysis appropriate for diverse family 
structures, including twins, sibships, and extended pedigrees (Supplementary 
Information).
After initial sample and variant QC, principal components analysis (PCA) 
was used to identify population outliers for exclusion and to stratify samples in 
each study by continental ancestry. Identified EU and AA ancestry populations 
were confirmed by PCA using the 1000 Genomes Project reference panel21 
(Supplementary Fig. 12). Ancestry within these two groups was accounted for 
with principal components. Final sample and variant QC, including filters for call 
rate, heterozygosity, and departure from Hardy–Weinberg equilibrium (HWE), 
was then performed within each ancestry group in each cohort. Samples were 
also filtered for cryptic relatedness and for departures from reported pedigree 
structures (Supplementary Information and Nature Research Reporting Summary).
Each cohort was imputed using SHAPEIT51 and IMPUTE252, using the 
cosmopolitan (all ancestries) 1000 Genomes Project reference panel consistent 
with prior recommendations53 (see also refs 47,54,55). Concordance of MAFs with 
the reference panel was verified before imputation, with SNPs in EU cohorts 
compared to MAF in European population samples and AA cohorts compared to 
MAF in African population samples (Supplementary Information). Instances of 
cryptic relatedness between cohorts were identified and excluded after imputation 
(Supplementary Information). Imputed SNPs were then filtered for INFO score  
> 0.8 and allele frequency > 0.01 before analysis.
Association analysis. A GWAS of AD status was performed within each ancestry 
stratum of each sample using an association model appropriate for the study 
design (Table 1 and Supplementary Table 1). For case–control studies, GWAS 
was performed using logistic regression with imputed dosages. For family-based 
studies of small, simple pedigrees (for example, sibships), association with imputed 
genotypes was tested using generalized estimating equations (GEE). For more 
complex pedigrees, imputed genotypes were tested using logistic mixed models. 
Sex was included as a covariate, along with principal components to control for 
population structure (Supplementary Information, Supplementary Note, and 
Supplementary Figs. 13 and 14).
In addition to this primary analysis, subsets of genetically unrelated  
individuals were selected from each family-based cohort (i.e., the most severe  
case in each family, by symptom count, was selected, followed by selection of 
unrelated/married-in controls) and used to perform a conventional case–control 
GWAS using logistic regression. This was used in place of the family-based  
GWAS for estimation of effect sizes and LD score regression analyses 
(Supplementary Table 2).
Genome-wide meta-analysis. The primary discovery meta-analysis of all ancestry-
stratified GWAS (ncase = 14,904; ncontrol = 37,944) was conducted in METAL56. As the 
different study designs (family vs. case–control) produced effect sizes that were 
not comparable, results were combined using weighting by effective sample size 
(Supplementary Information and Supplementary Note). Separate ancestry-specific 
discovery meta-analyses of EU (n = 46,568) and AA (n = 6,280) cohorts were also 
performed. Heterogeneity was evaluated across all cohorts and between study 
designs (Supplementary Information).
In addition to the discovery meta-analyses, we conducted meta-analyses for 
two design subsets. First, we performed sample size weighted meta-analysis of the 
subset of genetically unrelated individuals in EU (n = 38,686) and AA (n = 5,799) 
cohorts for use in LD score regression (LDSR) analysis. Second, we performed 
inverse-variance weighted meta-analysis of genetically unrelated individuals in 
genotyped cohorts to estimate within-ancestry effect sizes for EU (n = 28,757) and 
AA (n = 5,799). These effect sizes were then used to compare transancestral fine 
mapping results using inverse-variance weighted fixed effects, random effects57, 
and Bayesian58 models (Supplementary Information). Supplementary Table 2 
summarizes all of the meta-analytic models considered in the current analysis.
Replication. A novel locus on chromosome 3 was genome-wide significant (GWS) 
in the transancestral discovery meta-analysis. To seek replication, we examined the 
association between this locus and DSM-IV AD in two independent AA samples: 
Yale–Penn 2 (911 individuals with AD; 599 controls; tested using GEE) and COGA 
AAfGWAS (880 individuals with AD; 1,814 controls; tested using GWAF59). 
Association with AD status, broadly defined using hospital and death records, was 
also examined in the FINRISK cohort (1,232 individuals with AD; 22,614 controls) 
using Firth logistic regression60 (Supplementary Information and Nature Research 
Reporting Summary).
Power analysis. Post hoc power analysis was performed for odds ratios ranging 
from 1.05 to 1.30 and across allele frequencies using CaTS61 with the estimated 
effective sample size. Power analysis identifies the range of SNP effect sizes the 
current study was likely to detect at genome-wide significance if such effects 
exist. Additionally, we made specific comparisons to the distribution of effects 
for schizophrenia47, obesity62, and major depression48 as meaningful benchmarks 
to understand the magnitude of effect sizes plausible for AD (Supplementary 
Information and Nature Research Reporting Summary).
Heritability and genetic correlation analysis. LDSR analysis63 was performed to 
estimate the heritability explained by common SNPs in meta-analyses of unrelated 
EU and AA samples, respectively. LDSR was performed using HapMap3 SNPs and 
LD scores computed from 1000 Genomes Project reference samples corresponding 
to each population (Supplementary Information). Conversion of h2g estimates from 
observed to liability scale64 was performed assuming population prevalences of 
0.159 and 0.111 for AD in alcohol-exposed EU and AA individuals, respectively3. 
Gene-level enrichments were also tested with MAGMA15 (Supplementary 
Information).
Genetic correlations between AD and 45 traits from LD Hub25 and other 
published studies16–19,65–71 were examined using LDSR with the same unrelated EU 
meta-analysis (10,206 individuals with AD and 28,480 controls) and precomputed 
European ancestry LD scores. LDSR compares GWAS results for pairs of traits to 
estimate the correlation in the genetic liabilities explained by all common SNPs in 
the LD reference panel. To avoid increasing the multiple-testing burden, redundant 
or highly correlated phenotypes were reduced by manually selecting the version of 
the phenotype with the greatest predicted relevance to AD, largest sample size, or 
highest heritability (Supplementary Information).
Polygenic risk scores. To test the generalizability of the current GWAS 
results, polygenic risk scores (PRS) were computed in three external cohorts 
(Supplementary Information and Nature Research Reporting Summary). PRS 
computed from EU ancestry results were used to predict alcohol dependence in 
ALSPAC72,73 and COGA AAfGWAS, and CAGE screener scores in Generation 
Scotland (GS)74. PRS based upon the AA results were used to predict alcohol 
dependence in COGA AAfGWAS (Supplementary Information).
Accession codes. Comorbidity and Trauma Study: dbGap phs000277.v1.p1.
Center for Education and Drug Abuse Research: dbGap phs001649.v1.p1.
Christchurch Health and Development Study: dbGap submission in process.
COGA: dbGap phs000125.v1.p1, phs000763.v1.p1, and phs000976.v1.p1.
SAGE: dbGap phs000092.v1.p1.
COGEND: dbGap phs000404.v1.p1.
GEDI Duke University (GSMS): dbGap phs000852.v1.p1.
Center on Antisocial Drug Dependence: dbGap submission in process.
Spit for Science: dbGap submission in process.
NIAAA: available via https://btris.nih.gov/.
 GEDI Virginia Commonwealth University (VTSABD): dbGap submission  
in process.
Minnesota Center for Twin and Family Research: dbGap phs000620.v1.p1.
Yale–Penn: dbGap phs000425.v1.p1 and phs000952.v1.p1.
See Data Availability for information on accessing other cohorts.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Code availability. Code for GWAS of case/control cohorts with Ricopili is available 
at https://github.com/Nealelab/ricopili. Code for GWAS of family-based cohorts 
with Picopili is available at https://github.com/Nealelab/picopili. Code and 
reference data for LD score regression analyses are available at https://github.com/
bulik/ldsc. Effective sample size calculations were implemented using output from 
PLINK (https://www.cog-genomics.org/plink2), GMMAT (https://content.sph.
harvard.edu/xlin/software.html#gmmat), and geepack (https://cran.r-project.org/
web/packages/geepack/index.html) in R (https://cran.r-project.org/); stand-alone 
software for this purpose hasn’t been written but example code is available from the 
first author upon reasonable request.
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Data availability
Summary statistics from the genome-wide meta-analyses are available on the 
Psychiatric Genomics Consortium’s downloads page (http://www.med.unc.edu/
pgc/results-and-downloads), including the source data for Figs. 1 and 2. Individual-
level data from the genotyped cohorts and cohort-level summary statistics will be 
made available to researchers following an approved analysis proposal through 
the PGC Substance Use Disorder group with agreement of the cohort PIs; contact 
the corresponding authors for details. Cohort data are also available from dbGaP 
except where prohibited by IRB or European Union data restrictions. Expression 
data used to evaluate variants in ADH1B is available from GTEx (https://gtexportal.
org/home/). Hi-C data used to evaluate the chromosome 3 variant can be queried 
with HUGIn (https://yunliweb.its.unc.edu/hugin/). Publicly available genome-
wide summary statistics used for testing genetic correlations are accessible through 
LD Hub (http://ldsc.broadinstitute.org/) or from the Psychiatric Genomics 
Consortium (http://www.med.unc.edu/pgc/results-and-downloads), the Social 
Science Genetic Association Consortium (SSGAC; https://www.thessgac.org/data), 
Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA; http://
enigma.ini.usc.edu/research/download-enigma-gwas-results/), and the Neale Lab 
(http://www.nealelab.is/uk-biobank); for availability of summary statistics from 
other studies, contact the respective authors. The source data for Fig. 3 is included 
in Supplementary Table 6.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection Data collecting (phenotyping and genotyping) was performed previously by each cohort. Details on data collection in each cohort have 
been described previously, see the Supplementary Information for a full list of references. Broadly, phenotyping was not specifically 
dependent on specialized software (though may have, for example, been stored in a software system such as REDCap, https://
projectredcap.org/), and genotyping was performed using standard genotype calling pipelines outside of the scope of the current study.
Data analysis Quality control, imputation, and GWAS of case/control cohorts was performed using ricopili (https://github.com/Nealelab/ricopili), which 
includes wrappers around PLINK, Eigenstrat, LifeOver, SHAPEIT, IMPUTE2, and METAL. Quality control, imputation, and GWAS of family-
based cohorts was performed with picopili (https://github.com/Nealelab/picopili), which additionally includes wrappers of PRIMUS, 
ADMIXTURE, REAP, GMMAT, and geepack. Trans-ancestral meta-analyses were performed with METASOFT and MANTRA. PRSice was 
used for polygenic risk score analyses. 
 
LD score regression analyses were performed with ldsc (https://github.com/bulik/ldsc) and the LD Hub web tool (ldsc.broadinstitute.org). 
Gene-based analyses were performed with the FUMA web tool (http://fuma.ctglab.nl/), which uses MAGMA. Analyses related to local 
ancestry calling included scripts from Alicia Martin (https://github.com/armartin/ancestry_pipeline) using HAPI-UR and RFMix. Power 
analysis was performed using CaTS.  
 
Plots were generated using R, LocusZoom (http://locuszoom.org/), LDlink (https://analysistools.nci.nih.gov/LDlink/), and HUGIn (https://
yunliweb.its.unc.edu/hugin/). 
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All of the above are publicly available, with the exception of MANTRA which is available from the method's developer (Andrew Morris). 
Relevant links and citations are all provided in the manuscript. 
 
Remaining calculations, most notably the effective sample size calculations used for meta-analyses across study designs/association 
models, were performed using ad hoc scripts. Example code is available from the first author by request.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Summary statistics from the genome-wide meta-analyses are available on the Psychiatric Genomics Consortium’s downloads page (http://www.med.unc.edu/pgc/
results-and-downloads), including the source data for Figures 1 and 2. Individual-level data from the genotyped cohorts and cohort-level summary statistics will be 
made available to researchers following an approved analysis proposal through the PGC Substance Use Disorder group with agreement of the cohort PIs; contact 
the corresponding authors for details. Cohort data are also available from dbGaP except where prohibited by IRB or European Union data restrictions. Expression 
data used to evaluate variants in ADH1B is available from GTEx (https://gtexportal.org/home/). Hi-C data used to evaluate the chromosome 3 variant can be queried 
with HUGIn (https://yunliweb.its.unc.edu/hugin/). Publicly available genome-wide summary statistics used for testing genetic correlations are accessible through LD 
Hub (http://ldsc.broadinstitute.org/), or from the Psychiatric Genomics Consortium (http://www.med.unc.edu/pgc/results-and-downloads), the Social Science 
Genetic Association Consortium (SSGAC; https://www.thessgac.org/data), Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA; http://
enigma.ini.usc.edu/research/download-enigma-gwas-results/), and the Neale Lab (http://www.nealelab.is/uk-biobank); for availability of summary statistics from 
other studies contact the respective authors. The source data for Figure 3 is included in Supplementary Table S6. 
 
Accession Codes 
Comorbidity and Trauma Study (CATS): dbGAP accession phs000277.v1.p1  
Center for Education and Drug Abuse Research (CEDAR): dbGAP accession phs001649.v1.p1 
Christchurch Health and Development Study (CHDS): dbGAP submission in process 
The Collaborative Study on the Genetics of Alcoholism (COGA): dbGaP accession numbers  phs000125.v1.p1, phs000763.v1.p1, and phs000976.v1.p1 
Study of Addiction: Genetics and Environment (SAGE): dbGAP accession phs000092.v1.p1 
Collaborative Genetic Study of Nicotine Dependence (COGEND): dbGAP accession phs000404.v1.p1 
Gene-Environment-Development Initiative (GEDI) – Duke University (GSMS): dbGAP accession phs000852.v1.p1 
Center on Antisocial Drug Dependence (CADD): dbGAP submission in process 
Spit for Science: dbGAP submission in process 
NIAAA: available via https://btris.nih.gov/ 
Gene-Environment-Development Initiative (GEDI) –Virginia Commonwealth University (VTSABD): dbGAP submission in process 
Minnesota Center for Twin and Family Research (MCTFR): dbGAP accession phs000620.v1.p1 
Yale-Penn: dbGAP accession phs000425.v1.p1 and phs000952.v1.p1 
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Sample size was not predetermined, but instead reflects our best effort to aggregate all possible studies with genome-wide genotype data 
and robust phenotyping of alcohol dependence according to the DSM-IV criteria used in the current study. This open, international 
collaboration supported by the Psychiatric Genomics Consortium includes contributions from 28 studies (plus 3 replication cohorts and 2 ), 
and to our knowledge represents the largest genome-wide study of alcohol dependence to date. 
 
Based on the available data, we have made efforts to maximize the use of the genotyped samples. This includes developing the infrastructure 
and appropriate statistical modeling to include both family-based and case/control cohorts in the same genome-wide analysis, and including 
trans-ancestral analysis of both European and African ancestry individuals. 
 
We have also performed power analysis for the current genome-wide study, as detailed in the manuscript. For instance, we estimate that the 
full discovery meta-analysis has >80% power to detect variants associated with alcohol dependence with true odds ratios >= 1.15 and minor 
allele frequency > 0.15. We have also provided comparisons of power with other GWAS (e.g., schizophrenia, depression, obesity). This power 
and sample size are consistent with successful GWAS of many other complex traits.
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Data exclusions Data exclusions were performed based on (a) failure of pre-determined data quality control criteria and (b) planned phenotype exclusions to 
avoid confounds in defining alcohol dependence cases and controls. 
 
For quality control, individuals were excluded if they were observed to have low genotyping quality (i.e. high missingness rates), excess 
heterozygosity (an indicator of possible sample contamination or other technical artifacts), or if they deviated from reported family pedigree 
structures (i.e. excessive mendelian error rates, discordance between genetically-inferred and reported sex, cryptic genetic relatedness to 
unrelated individuals, or lack of expected genetic relatedness to members of the same pedigree). Observed outliers of genetic ancestry, as 
determined by principal components analysis, were also excluded in order to avoid the known risk of population stratification in genome-wide 
studies including such individuals. Ancestries other than African or European were excluded due to insufficient sample size for a meaningful 
analysis in the currently available data. 
 
For phenotype-based exclusions, we omit individuals lacking phenotype information for alcohol dependence, individuals who report never 
being exposed to alcohol, and individuals meeting criteria for alcohol abuse (i.e. qualifying neither as alcohol dependence cases or healthy 
controls). Cohorts with other exclusion criteria as part of their original study recruitment are detailed in the Supplementary Information. 
 
The metrics used as exclusion criteria were established prior to the analyses, but some thresholds used for exclusion (e.g. threshold from 
principal components analysis to define ancestry strata) were evaluated during the QC process. All of the above exclusions were made in 
accordance with the planned study protocol, and are detailed in the manuscript.
Replication The primary genome-wide significant locus identified in the current study (i.e. the ADH1B locus) is itself a replication of previous studies of 
alcohol dependence (see manuscript for references).  
 
For the novel genome-wide significant locus on chromosome 3, we present more targeted replication analysis from 3 additional cohorts of 
African and Finnish ancestries relevant to the putative signal. As described in the manuscript, replication was not found. We rely on this lack of 
replication to conclude that there is not sufficient evidence for an effect of the chr. 3 locus, with the result observed in the discovery sample 
potentially reflecting confounding from ancestry or an increased multiple testing burden. 
We also evaluate the consistency of effects in this locus between European and African ancestry cohorts and across study designs as a form of 
internal replication. These tests find very little evidence of any heterogeneity, indicating that the reported results have generally consistent 
evidence across ancestry and study design. Polygenic risk score analyses also provide generalizability of the overall results in both European 
and African ancestry cohorts. In all instances, polygenic risk scores derived from effect sizes in this study successfully predicted alcohol-related 
phenotypes in other studies as expected. The only instance of poor prediction was that effect sizes from the EA discovery GWAS in this study 
only weakly predicted alcohol dependence in an independent AA sample (COGA AAfGWAS), which is consistent with prior observations about 
cross-population polygenic prediction. 
 
The strong sample size requirements of the secondary analyses (most notably LD score regression analyses of heritability and genetic 
correlation to other traits) and dependence on LD reference panels limits options for direct replication of those findings. We instead focus on 
comparisons to existing GWAS of other alcohol-related phenotypes to get potential insight into how genome-wide results appear to 
generalize between these phenotypes in different study populations. The compelling findings from those comparisons are a key result for the 
current analysis and are discussed at length in the manuscript.
Randomization Randomization of experimental groups was not applicable to this study. The experimental conditions are determined by each individual's 
genetics, which are fixed at conception. Conceptually this reflects a randomization of the alleles inherited from each individual's parents (i.e. 
mendelian randomization), but it does not involve randomization of  experimental conditions by the researchers in a classical sense. Our study 
assess the observed association between that natural randomization of genotype and the ascertained phenotype of alcohol dependence.
Blinding Blinding is not relevant to the current study. Samples were not allocated to different conditions by the researches, and the phenotype 
ascertainment process is fully separate from the genotyping process. 
Reporting for specific materials, systems and methods
Materials & experimental systems
n/a Involved in the study
Unique biological materials
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Human research participants
Policy information about studies involving human research participants
Population characteristics The current study encompasses 14,904 cases and 37,944 controls from 28 cohorts in the primary analysis (after quality control), 
with an additional 2,997 cases and 25,318 controls from 3 replication cohorts and 9,629 individuals in 2 other cohorts used for 
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polygenic risk score analysis. Details on each cohort are provided in the manuscript, with summary descriptives in Table 1 and 
full descriptions in the Supplementary Information. 
 
Briefly, included participants represent a mix of ascertainment schemes across cohorts, including both population-based 
collections and ascertained research cohorts. These include studies of genetically unrelated cases and controls, as well as family-
based studies ranging from sibling pairs to extended pedigrees ascertained for enrichment of substance abuse. Overall, the 
participants include roughly equal numbers of males and females, with ages fully distributed across the lifespan for adults. 
Participants are from North America, Europe, and Australia and are of European or African ancestry (confirmed in genetic data), 
with African ancestry individuals predominantly reflecting African-American admixture.  
 
Genome-wide genotype data has been collected for all participants. Most individuals in the primary analysis were analyzed using 
the individual level genotype data, but a subset (N=9,929 from 5 cohorts) are only represented in summary statistics from their 
respective cohorts. The 3 replication cohorts are also only analyzed through contributed summary statistics. 
 
Phenotyping criteria vary by cohort (full descriptions in the manuscript supplement), but for most cohorts a standardized 
measure such as the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) or the Composite International 
Diagnostic Interview (CIDI) has been administered to ascertain lifetime alcohol dependence status in accordance with DSM-IV 
diagnostic guidelines. Current treatment data has not been collected for all participants, but is not critical to the current research 
question of genetic associations with lifetime dependence diagnosis.
Recruitment Participants were recruited separately for each cohort according to their respective study design. Descriptions of the design for 
each cohort can be found in the Supplementary Information, along with references to previous publications containing complete 
details.  
 
Overall, the cohorts represent a mix of population-based cohorts without targeted ascertainment (e.g. birth cohorts from a 
specified region), cohorts recruited for studies of alcohol dependence (e.g. families of probands from inpatient or outpatient 
treatment facilities), or cohorts originally recruited for studies of other substance dependence (e.g. cocaine or nicotine) or other 
phenotypes where measures of alcohol dependence were included in phenotyping (e.g. schizophrenia, high-risk populations 
involved in the criminal justice system, or pharmacogenetics studies).  
 
These recruitment strategies could yield biases in the results for a given cohort, but the mix of recruitment strategies used across 
the cohorts is unlikely to produces consistent biases across the current analysis. Instead, any different biases resulting from the 
variety of recruitment strategies and study designs would be more likely to manifest as heterogeneity or noise in results across 
the cohorts, potentially reducing power.
